Adrenomedullin promotes differentiation of oligodendrocyte precursor cells into myelin-basic-protein expressing oligodendrocytes under pathological conditions in vitro  by Maki, Takakuni et al.
Ava i l ab l e on l i ne a t www.sc i enced i r ec t . com
ScienceDirect
www.e l sev i e r . com / l oca te / s c r
Stem Cell Research (2015) 15, 68–74SHORT REPORTAdrenomedullin promotes differentiation of




Takakuni Maki a, Yoko Takahashi a,b, Nobukazu Miyamotoa, Anna C. Lianga,
Masafumi Ihara c, Eng H. Loa, Ken Arai a,⁎a Neuroprotection Research Laboratory, Departments of Radiology and Neurology, MA General Hospital,
Harvard Medical School, USA
b Department of Developmental Neuroscience, United Centers for Advanced Research and Translational Medicine,
Tohoku University School of Medicine, Sendai, Japan
c Department of Stroke and Cerebrovascular Diseases, National Cerebral and Cardiovascular Center, Osaka, JapanReceived 24 November 2014; received in revised form 25 April 2015; accepted 3 May 2015
Available online 9 May 2015Abstract
Oligodendrocytes, which are the main cell type in cerebral white matter, are generated from their precursor cells
(oligodendrocyte precursor cells: OPCs). However, the differentiation from OPCs to oligodendrocytes is disturbed under
stressed conditions. Therefore, drugs that can improve oligodendrocyte regeneration may be effective for white
matter-related diseases. Here we show that a vasoactive peptide adrenomedullin (AM) promotes the in vitro differentiation
of OPCs under pathological conditions. Primary OPCs were prepared from neonatal rat brains, and differentiated into
myelin-basic-protein expressing oligodendrocytes over time. This in vitro OPC differentiation was inhibited by prolonged
chemical hypoxic stress induced by non-lethal CoCl2 treatment. However, AM promoted the OPC differentiation under the
hypoxic stress conditions, and the AM receptor antagonist AM22–52 canceled the AM-induced OPC differentiation. In addition,
AM treatment increased the phosphorylation level of Akt in OPC cultures, and correspondingly, the PI3K/Akt inhibitor LY294002
blocked the AM-induced OPC differentiation. Taken together, AM treatment rescued OPC maturation under pathological
conditions via an AM-receptor-PI3K/Akt pathway. Oligodendrocytes play critical roles in white matter by forming myelin
sheath. Therefore, AM signaling may be a promising therapeutic target to boost oligodendrocyte regeneration in CNS disorders.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).⁎ Corresponding author at: Neuroprotection Research Laboratory, MGH East 149-2401, Charlestown, MA 02129, USA.
E-mail address: karai@partners.org (K. Arai).
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1873-5061/© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
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Oligodendrocytes are one of the major cell types in the
cerebral white matters. They produce a lipid-rich membrane
called myelin, which enwrap up to 60 axonal segments each
(i.e. myelin sheath). Myelin sheaths enable effective nerve
impulse conduction and play a supporting role for axons and
neuron homeostasis (Baumann and Pham-Dinh, 2001). During
development, oligodendrocyte precursor cells (OPCs) are
generated from germinal zones, then proliferate and
migrate to both gray and white matter areas, where most
of them differentiate into mature oligodendrocytes and
form myelin sheaths. However, some OPCs may persist in an
immature state. These residual OPCs are widely distributed
in adult brains, comprising 5–8% of all cells (Levine et al.,
2001). Although myelinated tracts are formed early in life,
renewal of myelin and oligodendrocyte continues through-
out most of the adult life (Paus et al., 1999; Young et al.,
2013; Dimou et al., 2008). In fact, myelin sheaths in the
adult CNS exhibit some plasticity in response to changes in
neural activity (Scholz et al., 2009) and brain injury
(Nait-Oumesmar et al., 2008). Residual OPCs may play an
important part in these endogenous mechanisms of white
matter repair and renewal.
In demyelinating diseases, injury of myelin/oligodendro-
cytes results in a profound loss of myelin sheaths, axonal
injury and degeneration, which eventually lead to long-lasting
functional disabilities (Franklin and Ffrench-Constant, 2008;
Emery, 2010). Mouse models of oligodendrocyte injury, such as
proteolipid protein (plp1)-null mice or Cnp mutant mice, show
axon loss without considerable demyelination (Griffiths et al.,
1998; Lappe-Siefke et al., 2003), suggesting that oligodendro-
cytes may also support axon survival through a myelin-
independent mechanisms (Funfschilling et al., 2012). Endoge-
nous repair attempts by OPC proliferation and differentiation
would occur at the early stage of demyelinating disorders but
often fail as disease progresses (Maki et al., 2013). Although no
clinically proven agents currently exist to protect/support OPCs
under prolonged or acute pathological conditions, enhancement
of oligodendrogenesis (regeneration of mature myelinating
oligodendrocytes) should be a promising approach for treatment
of demyelinating diseases (Franklin and Ffrench-Constant, 2008;
Kotter et al., 2011).
One potential target candidate for promoting oligoden-
drogenesis during pathological conditions may be adreno-
medullin (AM). AM was discovered as a vasoactive peptide
from human pheochromocytoma in 1993 (Kitamura et al.,
1993; Kato et al., 2005). AM is widely distributed in tissues,
and secreted from various organs such as adrenal medulla,
heart, kidney, lung, and vascular wall as well as the brain.
AM has diverse biological actions, including cell proliferation
and differentiation in a paracrine and autocrine manner
(Hinson et al., 2000; Martinez-Herrero et al., 2012; Lopez
and Martinez, 2002; Shindo et al., 2013). AM also have
important roles for cellular function of immature cells, such
as endothelial progenitor cell (EPC), mesenchymal stem cell,
hematopoietic stem cell, adrenocortical stem cell, and
neural stem/progenitor cell (NSPC) (Martinez-Herrero et
al., 2012; Larrayoz et al., 2012; Vergano-Vera et al., 2010).
Recently, it has been reported that AM may also regulate
white matter function in the brain. In a mouse model of
white matter injury by prolonged cerebral hypoperfusion,increased levels of circulating AM preserved oligodendrocyte/
myelin integrity along with restoring cerebral hemodynamic,
promoting arteriogenesis/angiogenesis, and alleviating oxida-
tive damage in cerebral microvessels (Maki et al., 2011a,b). In
addition, AM deficiency exacerbatedwhitematter injury during
prolonged cerebral hypoperfusion conditions (Mitome-Mishima
et al., 2014). However, mechanisms that underlie the ability of
AM to protect myelin and oligodendrocytes in damaged white
matter remain unclear. In this proof-of concept study, we
tested the hypothesis that AM can promote OPC differentiation
under pathological conditions.
Materials and methods
All experiments were performed following protocols
approved by the Massachusetts General Hospital Institution-
al Animal Care and Use Committee in accordance with the
National Institutes of Health Guide for the Care and Use of
Laboratory Animals.
Reagents
AM and AM receptor antagonists AM22–52 were purchased
from Peptide Institute Inc., and dissolved in distilled water.
CoCl2 and LY294002 were purchased from Sigma, and
dissolved in dimethysulphoxide. The final concentration of
dimethysulphoxide in the culture medium was less than
0.1%, which had no effect on OPC survival and function.
Cell culture
OPCs were prepared as previously described (Arai and Lo, 2009;
Pham et al., 2012). Briefly, cerebral cortices from 1–2 day old
Sprague Dawley rats were dissected, minced, and digested.
Dissociated cells were plated in poly-D-lysine-coated 75 cm2
flasks, and maintained in Dulbecco's Modified Eagle's Medium
(DMEM) containing 20% heat-inactivated fetal bovine serum and
1% penicillin/streptomycin. After the cells were confluent
(~10 days), the flasks were shaken for 1 h on an orbital shaker
(218 rpm) at 37 °C to removemicroglia. They are then changed
to newmedium and shaken overnight (~20 h). The mediumwas
collected and plated on non-coated tissue culture dishes for 1 h
at 37 °C to eliminate contaminating astrocytes and microglia.
The non-adherent cells were collected and replated in
Neurobasal (NB) medium containing 2 mM glutamine, 1%
penicillin/streptomycin, 10 ng/ml PDGF, 10 ng/ml FGF, and
2% B27 supplement onto poly-DL-ornithine-coated plates. Four
to 5 days after plating, the OPCs were used for the experi-
ments. To differentiate OPCs to oligodendrocytes, the culture
medium was switched to DMEM containing 1% penicillin/
streptomycin, 10 ng/ml CNTF, 15 nM T3, and 2% B27
supplement.
CoCl2 treatment
To mimic hypoxic conditions in vitro, cells were incubated
with non-lethal concentration of cobalt chloride (CoCl2)
according to our previous reports (Miyamoto et al.,
2013a,b). For experiments in Figs. 1 and 3, cells were
maintained in the differentiation culture media with or
Figure 1 AM promoted OPC differentiation under prolonged hypoxic conditions. (A) Cultured rat OPCs were maintained in the
differentiation media for 7 days. Under normal conditions, the OPCs were successfully maturated into MBP-expressing
oligodendrocytes. On the other hand, when OPCs were incubated with non-lethal 1 μM CoCl2 (e.g. chemical hypoxic conditions),
they were not differentiated. However, AM treatment (10 nM) promoted the in vitro OPC differentiation under the stressed
conditions. MBP is a marker for mature oligodendrocytes. Scale bar = 200 nm. (B–C) Western blot analyses also confirmed that the
hypoxic conditions disturbed the OPC differentiation but AM promoted the process. MBP is a marker for mature oligodendrocytes, and
β-actin is an internal control. Percentages of MBP expression were calculated based on the values in control group (i.e. no CoCl2
stress). Values are mean ± SD from 4 independent experiments. *P b 0.05. (D) The WST assay showed that either AM or CoCl2 did not
induce overt cell death in our OPC culture system. Percentages of WST activity were calculated based on the values in control group
(i.e. no CoCl2 stress). Values are mean ± SD from 4 independent experiments.
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media containing CoCl2 were applied to OPC cultures on days 0,
3, and 5 (i.e. after starting OPC differentiation, we changed
the culturemedia on days 3 and 5). Then on day 7 after starting
OPC differentiation, cells were used for cell proliferation/
survival assay, immunocytochemistry, and western blot. For
experiments in Suppl Fig. S1, cells were maintained in the
differentiation culture media for 7 days. We prepared four
groups: (i) control (no CoCl2 stress), (ii) 1 μMCoCl2 (for 7 days),
(iii) 1 μM CoCl2 (for 7 days) plus 10 nM AM (for 7 days), and
(iv) 1 μMCoCl2 (for 7 days) plus 10 nM AM (from day 0 to day 1).
After starting OPC differentiation, we changed the cultured
media on days 1, 3, 5 and then on day 7, cells were used for
western blot.Cell proliferation/survival assay
Cell proliferation/survival was assessed by WST reduction
assay (Cell Counting Kit-8, Dojindo). WST assay is a sensitive
colorimetric method to detect cell viability. Highly
water-soluble tetrazolium salt WST-8 is reduced by dehy-
drogenase activities in live cells to give a yellow-color
formazan dye, which is soluble in the tissue culture media.
Therefore, the intensity of the formazan dye can be anindicator correlating to the number of viable cells. The cells
were incubated with 10% WST solution for 1 h at 37 °C. Then
the absorbance of the culture medium was measured with a
microplate reader at a test wavelength of 450 nm and a
reference wavelength of 630 nm.
Immunocytochemistry
The cells were washed with ice-cold PBS, pH 7.4, followed
by 4% paraformaldehyde for 15 min. After being further
washed three times in PBS containing 0.1% Triton X-100,
they were incubated with 1% bovine serum albumin in PBS
for 1 h. Then cells were incubated with primary antibodies
against MBP (1:100, Thermo Scientific) at 4 °C overnight.
After washing with PBS, they were incubated with secondary
antibodies for 1 h at room temperature. Finally, nuclei were
counterstained with DAPI.
Western blotting
Cells were rinsed twice with ice-cold PBS, and the cells were
collected into cell lysis buffer (Pro-PREP™ Protein Extraction
Kit, iNtRON Biotechnology). After the protein concentrations
were quantified and adjusted to the same concentrations by
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of sample buffer containing 91% SDS (Novex) and 9%
2-mercaptoethanol (Sigma). Subsequently, samples were
heated at 95 °C for 5 min, and each sample was loaded onto
4–20% Tris–glycine gels. After electrophoresis and transfer-
ring to nitrocellulose membranes (Novex), the membranes
were blocked in Tris buffered saline with 0.1% Tween 20
(TBS-T) containing 5% nonfat dry milk for 60 min at room
temperature. Membranes were then incubated overnight at
4 °C with myelin basic protein (MBP) antibody (1:500,
Thermo Scientific), Akt antibody (1:1000, Cell Signaling),
phosphorylated Akt (Ser473) antibody (1:1000, Cell Signal-
ing), or anti-β-actin antibody (1:10000, Sigma Aldrich)
followed by incubation with peroxidase-conjugated second-
ary antibodies and visualization by enhanced chemilumines-
cence (Amersham).Statistical analysis
Experiments were performed in duplicate, repeated 3–4
times independently. Quantitative data were analyzed by
using ANOVA followed by post hoc Tukey test or Tukey–
Kramer test. All values are expressed as means ± SD. A value
of P b 0.05 was considered statistically significant.Results
Primary OPCs were prepared from rat neonatal cortex. When
OPCs were maintained in differentiation media (e.g. DMEM
plus 2% B27 including 10 ng/ml CNTF, 15 nM T3 over 7 days),
the cells began to exhibit oligodendrocyte-like phenotypes
with myelin-basic-protein (MBP) expression (Fig. 1A: control
group). As previously reported, OPC differentiation was
suppressed by prolonged hypoxia induced by non-lethal
CoCl2 treatment for 7 days (Miyamoto et al., 2013a,b)
(Fig. 1A: CoCl2-treated group). However, 7-day treatment
with AM rescued OPC differentiation under the prolonged
chemical hypoxic conditions (Fig. 1A: AM + CoCl2-treated
group). Western blot analyses confirmed that AM promoted
oligodendrocyte maturation under the stressed conditions
(Figs. 1B–C). However, 1-day AM treatment did not rescue
the OPC differentiation under the stressed conditions (Suppl
Fig. S1). A standard WST assay showed that neither AM nor
CoCl2 altered the OPC number or induced overt cell death in
our cell culture system (Fig. 1D).
We next examined the mechanisms that may underlie
AM-mediated rescue of OPC differentiation. Receptor-
mediated Akt signaling may be involved since AM treatment
increased the phosphorylation levels of Akt in OPCs within
30 min (Fig. 2A), and this Akt phosphorylation was back to
baseline in 24 h after AM treatment (Fig. 2B). AM-induced
Akt phosphorylation was inhibited by the PI3K inhibitor
LY294002 (Fig. 2C) or blockade of the AM receptor with
AM22–52 (Fig. 2D). Finally, blockade of PI3K/Akt signaling
with LY294002 or AM22–52 negated the ability of AM to rescue
OPC differentiation treatment under prolonged hypoxic
conditions (Figs. 3A–B). These effects were not due to
changes in cell survival since the WST assay once again
showed that there was no significant cell damage in our
experimental conditions (Fig. 3C).Discussion
In this study, we obtained proof-of-concept data to support
our hypothesis that AM can rescue OPC differentiation into
mature oligodendrocytes under pathological conditions. Our
pharmacological approaches also showed that the AM
receptor and PI3K/Akt would mediate these AM effects. AM
and its receptors are widely expressed in the central nervous
system (CNS) (Ueta et al., 1995; Serrano et al., 2002). Past
studies extensively examined the multiple roles of AM on
neuronal and vascular function. AM exerts various actions on
the vasculature, such as vasodilation, angiogenesis, and regula-
tion of blood brain barrier. Similarly, AM acts as a neurotrans-
mitter, neuromodulator, or neurohormone (Martinez-Herrero et
al., 2012). In addition, AM can be considered as a therapeutic
target for CNS diseases since several animal studies have
demonstrated that AM reduces neuronal injuries (Watanabe et
al., 2001; Miyashita et al., 2006; Xia et al., 2004, 2006).
Furthermore, compared to wild-type mice, brain-specific condi-
tional AM knockout mice or AM heterozygous KO mice exhibited
more neuronal damage after ischemic insults (Hurtado et al.,
2010; Miyamoto et al., 2009). In vitro cell culture studies also
confirmed that AM protected neurons against oxygen glucose
deprivation stress in an autocrine and paracrine manner
(Miyashita et al., 2006; Tixier et al., 2008). AM may also be
effective in the chronic phase as AM increased mobilization of
CD34+ mononuclear cells (so-called EPCs) and subsequent
vascular regeneration and neurogenesis after stroke (Miyashita
et al., 2006). Our current findings that AM can promote
oligodendrogenesis under pathological conditions may support
these past studies and confirm that the AM signalingwould be the
therapeutic target for neurological disorders, especially for
white matter-related diseases.
Neurons play the central role in the brain, and there-
fore, neuroprotection would be the most important
approach for CNS diseases. However, oligodendrocytes
(and oligodendrocyte-rich white matter) should also be
considered when we aim to develop efficient therapies for
brain protection. Compared to rodents, primates possess an
evolutionally expanded volume of white matter, and white
matter damage is a clinically important aspect of several CNS
diseases, such as stroke or vascular dementia (Benowitz and
Carmichael, 2010; Jiang et al., 2010; Yang and Rosenberg,
2011; Tosto et al., 2014; Philips and Rothstein, 2014). This
may explain the reasons why many neuroprotectants (e.g.
glutamate receptor antagonists, antioxidants, etc.) that were
proved neuroprotective in rodent CNS disease models have
failed to provide efficacy in clinical trials (Savitz and Fisher,
2007). Even small lesions in the white matter areas (corona
radiata or internal capsule) could lead to severe hemiplegia
and poor functional prognosis in humans because loss of
oligodendroglial supports can cause progressive axon/neuron
degeneration and long-term functional disability. Others and
we have previously demonstrated that AM might play an
important role in the preservation of oligodendrocyte and
white matter integrity in mousemodels of white matter injury
(Maki et al., 2011a,b; Mitome-Mishima et al., 2014).
For example, overexpression of circulating AM increased
GST-pi-positive oligodendrocytes and preserved myelin integ-
rity accompanied with promotion of neovascularization and
vasoprotection after prolonged cerebral hypoperfusion
in mice. This “oligo-vascular” protection may lead to the
Figure 2 AM increased the levels of Akt phosphorylation via AM-receptor-PI3K pathway. (A–B) Cultured rat OPCs were incubated
with 10 nM AM up to 24 h, and then cell lysates were subjected to western blot analyses with anti-p-Akt or anti-Akt antibodies. AM
treatment increased the levels of Akt phosphorylation without changing total Akt levels. Values are mean ± SD from 3 independent
experiments. (C) Under the conditions of 1 μM LY294002 (PI3K inhibitor) existence, AM did not increase the phosphorylation levels of
Akt. Values are mean ± SD from 3 independent experiments. (D) Similarly, AM did not increase the phosphorylation levels of Akt under
the conditions of 1 μM AM22–52 (AM-receptor antagonist) existence. Values are mean ± SD from 3 independent experiments.
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al., 2011a,b). In addition, a recent report showed that AM
knockout mice exhibited decreased OPCs and GST-pi-positive
oligodendrocytes and MBP expression in white matter after
prolonged cerebral hypoperfusion (Mitome-Mishima et al.,
2014). Here we show for the first time that AM would directly
work on OPCs to promote oligodendrogenesis under patholog-
ical conditions in vitro. These findings may explain the me-
chanisms for beneficial effects of AM onwhitematter integrity
and function. Therefore, the multiple actions of AM on
neuro-vascular-oligo protection/regeneration would have a
potential as a promising treatment for cerebrovascular
diseases.
Taken together, our findings support the hypothesis that
AM can rescue OPC differentiation via receptor-mediated
Akt signaling. However, there are some important caveats to
keep in mind. First, our current study used only a pure
cell culture system. However, to prove clinically-relevant
supportive/protective roles of AM on OPCs against stress, we
should test the efficacy of AM on in vivo white matter
injury animals. Second, our data indicate that short-term
AM treatment was not supportive for in vitro OPC differenti-
ation under pathological conditions. A single treatment ofAM could activate the downstream pathway (i.e. Akt phos-
phorylation), but to sufficiently drive the OPC differentiation,
multiple rounds of AM treatments would be required. Before
testing the efficacy of AM using in vivo animal models, further
investigation into the underlying mechanisms of AM/Akt-
induced OPC maturation is needed to identify effective
treatment schedules of AM. Third, we only examined the
PI3K/Akt pathway as an intracellular signaling pathway for in
vitro oligodendrogenesis by AM. But the AM receptor would
activate other cellular signaling pathways, such as MEK/ERK or
cAMP/PKA pathways (Nagaya et al., 2005). Whether these
pathways are also involved in the OPC-supportive effects of AM
should be carefully examined in future studies. Finally, as OPCs
are generated from NSPCs, we may also need to test if AM can
enhance the number of newly generated OPCs from NSPCs
after white matter injury. A recent study showed that lack of
AM results in profound changes in the proliferation and
differentiation rates in the progeny of NSPCs isolated from
the olfactory bulbs of AM deficient mice. NSPCs derived from
the AM deficient mice produced a lower proportion of
neuronal-astroglial lineage cells and a higher proportions of
oligodendrocyte lineage cells compared to NSPCs from WT
mice (Vergano-Vera et al., 2010). Hence, future studies are
Figure 3 AM-receptor-PI3K/Akt pathway mediated AM-induced OPC maturation. (A–B) Cultured rat OPCs were maintained in the
differentiation media for 7 days. The prolonged chemical hypoxic conditions by non-lethal 1 μM CoCl2 disturbed OPC maturation, but
AM treatment promoted the process. This AM-induced OPC maturation was inhibited by either co-treatment with 1 μM LY294002 (PI3K
inhibitor) or 1 μM AM22–52 (AM-receptor antagonist). Percentages of MBP expression were calculated based on the values in control
group (i.e. no CoCl2 stress). N = 3 of independent experiments. *P b 0.05. (B) The WST assay showed that in any treatment groups,
there was no significant OPC damage. Percentages of WST activity were calculated based on the values in control group (i.e. no CoCl2
stress). Values are mean ± SD from 3 independent experiments.
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under normal and pathological conditions.
In summary, our data provide proof-of-concept that AM
can promote and rescue OPC differentiation into mature
oligodendrocytes under pathological conditions in vitro.
Preservation and repair of oligodendrocytes should be an
important criteria of therapies for CNS disease patients.
Therefore, AM signaling may be a novel therapeutic target
for accelerating regenerative responses in demyelinating
conditions such as stroke, multiple sclerosis or vascular
dementia.
Supplementary data to this article can be found online at
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